Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of alisporivir (ALV; DEB025) triple therapy
[i.e., when added to peginterferon alfa-2a (PEG) and ribavirin (RBV)] to optimize treatment
in treatment-naïve participants with hepatitis C virus (HCV) genotype 1 (GT1)